steatohepatitis – Medxy AI

Advancing Diagnosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights from the LITMUS Multicentre Study

By MedXY 11/06/2026

The LITMUS study evaluates non-invasive biomarkers for diagnosing metabolic dysfunction-associated steatotic liver disease, highlighting proteomic panels' promise in detecting at-risk steatohepatitis and fibrosis stages, potentially replacing biopsy.

Gastroenterology news

An Unexpected Cause of Severe Steatohepatitis in a Young Male

By MedXY 10/05/2026

A 24-year-old obese male presents with incidental liver abnormalities; imaging reveals severe steatohepatitis with unusual features prompting detailed diagnostic evaluation and management strategies.

Diabetes & Endocrinology Gastroenterology news

Dual Agonism for MASH: Pemvidutide Achieves Rapid Histological Resolution in Phase 2b IMPACT Trial

By MedXY 01/13/2026

The Phase 2b IMPACT trial demonstrates that pemvidutide, a GLP-1/glucagon dual agonist, significantly achieves MASH resolution at 24 weeks without dose titration, though fibrosis improvement did not reach significance at this early timepoint.

Family Medicine & Nutrition Gastroenterology Medical News news Specialties

Waist Size Proves Key to Assessing Liver Health

By MedXY 08/06/2025

Waist circumference is a superior predictor of metabolic liver diseases, outperforming BMI and other body metrics in assessing MASLD, MASH, and liver stiffness risks.

Clinical Updates Gastroenterology Internal Medicine news Specialties

Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results

By MedXY 08/02/2025

Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled trial.